Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
12/2003
12/09/2003CA2140247C Novel vitamin d analogues
12/09/2003CA2123697C Novel substituted salicylic acids
12/09/2003CA2111580C Immunogen composites with noted anticytokin effect, process of preparation, pharmaceutical compositions and kits containing them
12/09/2003CA2104776C Thalidomide derivatives, method of manufacture and use thereof in medicaments
12/04/2003WO2003100438A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003WO2003100087A2 Regulation of novel human asparagine-hydroxylases
12/04/2003WO2003100045A1 Plant thymidine kinases and their use
12/04/2003WO2003099845A2 Fas peptide mimetics and uses thereof
12/04/2003WO2003099839A1 Modulators and inhibitors of fibroblast growth factor receptor 5_polypeptides and gene expression thereof.
12/04/2003WO2003099820A1 Pyrazolo-pyrimidine aniline compounds
12/04/2003WO2003099811A1 Kinase inhibitors
12/04/2003WO2003099808A1 Substituted heterocyclic compounds and methods of use
12/04/2003WO2003099807A1 New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
12/04/2003WO2003099805A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003WO2003099796A1 Protein kinase inhibitors
12/04/2003WO2003099795A1 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors
12/04/2003WO2003099781A2 METHODS FOR THE IDENTIFICATION OF IKKα FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
12/04/2003WO2003099773A1 Ccr9 inhibitors and methods of use thereof
12/04/2003WO2003099771A2 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003WO2003099765A1 β-ALANINE DERIVATIVE AND USE THEREOF
12/04/2003WO2003099334A1 Topically applicable pharmaceutical preparation
12/04/2003WO2003099327A1 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
12/04/2003WO2003099323A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003WO2003099317A1 Novel uses of cephaibols
12/04/2003WO2003099309A1 Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits
12/04/2003WO2003099308A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng
12/04/2003WO2003099284A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003WO2003099278A1 Ophthalmological use of roflumilast for the treatment of diseases of the eye
12/04/2003WO2003099274A1 Hepatitis c virus inhibitors
12/04/2003WO2003099270A1 Methods of treating allergic reactions
12/04/2003WO2003099226A2 Antibody peg positional isomers, compositions comprising same, and use thereof
12/04/2003WO2003099221A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003099037A1 Probiotics and oral tolerance
12/04/2003WO2003099011A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003080841A8 Calcineurin activators
12/04/2003WO2003072736A3 Reagents and treatment methods for autoimmune diseases
12/04/2003WO2003068201A3 High affinity antibody having a tcr-like specificity and use in detection and treatment
12/04/2003WO2003066810A3 Recombinant bovine immunodeficiency virus based gene transfer system
12/04/2003WO2003066604A3 Novel aryl- and heteroarylpiperazines
12/04/2003WO2003063794A3 2,4-pyrimidinediamine compounds and their uses
12/04/2003WO2003062200A3 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
12/04/2003WO2003050499A3 Use of a labeled ligand having human cd4 specificity
12/04/2003WO2003039523A3 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003008579A3 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002094186A3 Urazole compounds useful as anti-inflammatory agents
12/04/2003WO2002081519A9 Ifn-thy fusion protein,dna coding therefore,its preparation and application
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002069985A8 Immune response potentiation
12/04/2003WO2002068635A3 Methods of inhibiting expression of a target gene in mammalian cells
12/04/2003WO2002068397A8 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
12/04/2003WO2002057427A3 Mammalian tumor susceptibility gene products and their uses
12/04/2003WO2002055080A3 Method of immunomodulation using thione-forming disulfides
12/04/2003WO2002043774A3 Compositions and therapeutical use of polynucleotides encoding tcrs
12/04/2003WO2002036806A9 Expression vectors able to elicit improved immune response and methods of using same
12/04/2003WO1999013818A3 Membrane virus host range mutations and their uses as vaccine substrates
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
12/04/2003US20030225269 Inhibitors of interleukin-1beta converting enzyme
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225128 For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders
12/04/2003US20030225120 Dihydropyridine soft drugs, and related compositions and methods
12/04/2003US20030225111 Use of a quinazoline derivative such as 1-(2,6-dichloro-phenyl)-3-(7-(3-morpholinopropoxy)quinazolin-4-yl) urea to produce an antiangiogenic and/or vascular permeability reducing effect
12/04/2003US20030225103 Method of using diketopiperazines and composition containing them
12/04/2003US20030225094 E.g, 4-(2-((6R,12aR)-6-benzo(1,3)dioxol-5-yl-1,4-dioxo -3,4,6,7,12,12a-hexahydro-1H-pyrazino-(1',2':1,6)pyrido(3,4-b) indol-2-yl)ethyl)-benzenesulfonamide; inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase
12/04/2003US20030225093 Cyclic gmp-specific phosphodiesterase inhibitors
12/04/2003US20030225092 E.g., 6-Benzo(1,3)dioxol-5-yl-10-hydroxy-2-methyl-2,3,6,7,12, 12a-hexa-hydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase
12/04/2003US20030225089 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225071 N-heterocyclic amides and carbamates
12/04/2003US20030225065 Use of 4-(1,4-diazepan-1-yl)- or 4-piperazin-1-yl-2-aminophenyl phenyl sulfones for treatment of disorders of the central nervous system.
12/04/2003US20030225063 Treating autoimmune diseases mediated by cathepsin S
12/04/2003US20030225062 Treating autoimmune diseases mediated by cathepsin S
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224980 Diagnostic reagents for human cytomegalovirus and methods of use
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224423 Method of testing for allergic diseases
12/04/2003US20030224413 Comprises polynucleotides coding restriction fragment length polymorphism for use in identifying, characterizing and treatment of blood, respiratory, tumor and nervous system disorders
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030224008 Novel uses for anti-malarial therapeutic agents
12/04/2003US20030223994 Protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223970 Methods and compounds for prevention of graft rejection
12/04/2003US20030223964 Efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the
1 ... 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 ... 1172